Rivastigmine in the treatment of dementia: from the symptomatic effect to neuroprotection

Damulin I.V.

doi:https://doi.org/

References:

Zakharov V.V., Yakhno N.N. Sindrom umerennykh kognitivnykh rasstroistv v pozhilom vozraste: diagnostika i lechenie. Rus med zhurn 2004; 10: 573-576.
Kondrat'eva E.A., Borovikova V.N., Kondrat'ev S.A. i dr. Rol' rivastigmina (ekselona) v lechenii posledstvii cherepno-mozgovoi travmy. Zhurn nevrol i psikhiat 2009; 109: 55-58.
Lokshina A.B., Zakharov V.V. Legkie i umerennye kognitivnye rasstroistva pri distsirkulyatornoi entsefalopatii. Nevrol zhurn 2006; 11: pril. 1: 57-64.
Yakhno N.N. Kognitivnye rasstroistva v nevrologicheskoi klinike Nevrol zhurn 2006; 11: pril. 1: 4-13.
Bartzokis G. Acetylcholinesterase inhibitors may improve myelin integrity. Biol Psychiat 2007; 62: 294-301.
Bowler J.V. Acetylcholinesterase inhibitors for vascular dementia and Alzheimer's disease combined with cerebrovascular disease. Stroke 2003; 34: 584-586.
Brooks N. Mental deterioration late after head injury - does it happen? J Neurol Neurosurg Psychiat 2003; 74: 1014.
Brun A. The neuropathology of vascular dementia and its overlap with Alzheimer's disease. In: Cerebrovascular Disease, Cognitive Impairment and Dementia. Second edition. Ed. by J.O'Brien et al. London, New York: Martin Dunitz 2004; 103-115.
Bruton C.J. Head injury and dementia. In: The Neuropathology of Dementia. Ed. by M.M. Esiri, J.H. Morris. Cambridge: Cambridge University Press 1997; 344-355.
Bullock R. The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis. Int J Clin Pract 2002; 56: 3: 206-214.
Bullock R., Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Curr Med Res Opin 2002; 18: 5: 258-264.
Bullock R., Connolly C. Switching cholinesterase inhibitor therapy in Alzheimer's disease - donepezil to rivastigmine, is it worth it? Int J Geriat Psychiat 2002; 17: 288-289.
Bullock R., Lane R. Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase. Curr Alzheimer Res 2007; 4: 277-293.
Court J., Perry E.K., Kalaria R.N. Neurotransmitter changes in vascular dementia. In: Cerebrovascular Disease, Cognitive Impairment and Dementia. Second edition. Ed. by J.O'Brien et al. London, New York: Martin Dunitz 2004; 133-151.
Cummings J.L., Kaufer D. Neuropsychiatric aspects of Alzheimer's disease: The cholinergic hypothesis revisited. Neurology 1996; 47: 876-883.
Cummings J., Emre M., Aarsland D. et al. Effects of rivastigmine in Alzheimer's disease patients with and without hallucinations. J Alz Dis 2010; 20: 301-311.
Das N.U. Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation. Med Sci Monit 2007; 13: RA214-RA221.
de la Torre J.C., Stefano G.B. Evidence that Alzheimer's disease is a microvascular disorder: the role of constitutine nitric oxide. Brain Res Rev 2000; 34: 119-136.
Desmond D.W. Vascular dementia. Clin Neurosci Res 2004; 3: 437-448.
Doraiswamy P.M., Krishnan K.R.R., Anand R. et al. Long-term effects of rivastigmine in moderately severe Alzheimer's disease: Does early initiation of therapy offer sustained benefits? Progr. Neuro-Psychopharm. Biol Psychiat 2002; 26: 705-712.
Emre M., Aarsland D., Albanese A. et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509-2518.
Erkinjuntti T., Roman G., Gauthier S. et al. Emerging therapies for vascular dementia and vascular cognitive impairment. Stroke 2004; 35: 1010-1017.
Farlow M., Anand R., Messina J. et al. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 2000; 44: 234-241.
Farlow M.R., Lilly M.L. and for the ENA713 B352 Study Group. Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years. BMC Geriatrics 2005; 5: 3-10.
Farlow M.R., Cummings J.L. Effective pharmacologic management of Alzheimer's disease. Am J Med 2007; 120: 388-397.
Feldman H.H., Ferris S., Winblad B. et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 2007; 6: 501-512.
Ferris S., Lane R., Sfikas N. et al. Effects of gender on response to treatment with rivastigmine in mild cognitive impairment: a post hoc statistical modeling approach. Gender Med 2009; 6: 345-355.
Ferris S., Nordberg A., Soininen H. et al. Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment. Pharmacogenet. Genomics 2009; 19: 635-636.
Golde T.E. Alzheimer disease therapy: Can the amyloid cascade be halted? J Clin Invest 2003; 111: 11-18.
Gorelick P.B. Status of risk factors for dementia associated with stroke. Stroke 1997; 28: 459-463.
Grossberg G.T., Stahelin H.B., Messina J.C. et al. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications. Int J Geriat Psychiat 2000; 15: 242-247.
Guttman R., Altman R., Nielsen N.H. Alzheimer disease. Report of the Council on Scientific Affairs. Arch Fam Med 1999; 8: 347-353.
Holmin S., Gahm C., Mathiesen T. Intracerebral inflammatory response in traumatic brain injury. In: Research and Practice in Alzheimer's Disease. Vol.2. Ed. by B. Vellas, L.J. Fitten. Paris, New York: Serdi Publisher, Springer Publishing Company 1999; 48-54.
Hsu J.L., Leemans A., Bai C.H. et al. Gender differences and age-related white matter changes of the human brain: a diffusion tensor imaging study. NeuroImage 2008; 39: 566-577.
Kennedy J.S., Polinsky R.J., Johnson B. et al. Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans. J Clin Psychopharm 1999; 19: 6: 513-521.
Lane R.M., Potkin S.G., Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Internat. J Neuropsychopharmacol 2006; 9: 101-124.
Langa K.M., Foster N.L., Larson E.B. Mixed dementia. Emerging concepts and therapeutic implications. JAMA 2004; 292: 2901-2908.
Leys D., Henon H., Pasquier F. The role of cerebral infarcts in vascular dementia. /In: Research and Practice in Alzheimer's Disease. B. Vellas et al. (eds.). Paris: Serdi Publisher 2001; 5: 123-128.
Lojkowska W., Ryglewicz D., Jedrzejczak T. et al. The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia. J Neurol Sci 2003; 216: 119-126.
Lopez O.L., Becker J.T., Saxton J. et al. Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition. J Am Geriat Soc 2005; 53: 1: 83-87.
McKeith I., Del Ser T., Spano P.-F. et al. Efficacy of rivastigmine in patients with dementia with Lewy bodies: a randomized, double blind, placebo-controlled international study. Lancet 2000; 356: 2031-2036.
Meguro K., Ishii H., Yamaguchi S. et al. Is vascular cognitive impairment the preclinical stage of vascular dementia: The Tajiri Project. In: 2nd Congress of the International Society for Vascular Behavioural and Cognitive Disorders (Vas-Cog). Abstract book. Florence 2005; 71.
Moretti R., Torre P., Antonello R.M., Cazzato G. Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow-up. Eur J Neurol 2001; 8: 361-362.
Morganroth J., Graham S., Hartman R., Anand R. Electrocardiographic effects of rivastigmine. J Clin Pharmacol 2002; 42: 558-568.
Nizri E., Irony-Tur-Sinai M., Faranesh N. et al. Suppression of neuroinflammation and immunomodulation by the acetylcholinesterase inhibitor rivastigmine. J Neuroimmunol 2008; 203: 12-22.
Orgogozo J.-M. Therapeutic Approaches in Alzheimer's Disease. /In: Alzheimer's Dementia. The 16th International Bayer Pharma Press Seminar. Paris 1997; 34-42.
Perry E.K., Perry R.H., Blessed G., Tomlinson B.E. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 1978; 4: 273-277.
Perry E., Ziabreva I., Perry R. et al. Absence of cholinergic deficits in "pure" vascular dementia. Neurology 2005; 64: 132-133.
Petersen R. C., Stevens J.C., Ganguli M. et al. Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1133-1142.
Potkin S.G., Anand R., Hartman R. et al. Impact of Alzheimer's disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease. Progr. Neuro-Psychopharm. Biol Psychiat 2002; 26: 713-720.
Raskind M.A. Galantamine - a review of efficacy and tolerability in mild-to-moderate Alzheimer's disease. In: Alzheimer's Disease and Related Disorders: Research Advances. Ed. by K. Iqbal, B. Winblad. Bucharest: "Ana Aslan" International Academy of Aging 2003; 677-691.
Royall D.R. The emperor has no clothes: Dementia treatment on the Eve of the Aging Era. J Am Geriat Soc 2005; 53: 1: 163-164.
Shanks M., Kivipelto M., Bullock R., Lane R. Cholinesterase inhibition: is there evidence for disease-modifying effects? Curr Med Res Opin 2009; 25: 2439-2446.
Small G.W. What we need to know about age related memory loss. Br Med J 2002; 324: 1502-1505.
Smith G.S., De Leon M.J., George A.E. et al. Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease. Pathophysiologic implications. Arch Neurol 1992; 49: 1142-1150.
Tavassoli N., Sommet A., Lapeyre-Mestre M. et al. Drug interactions with cholinesterase inhibitors: An analysis of the French pharmacovigilance database and a comparison of two national drug formularies (Vidal, British National Formulary). Drug Safety 2007; 30: 1063-1071.
Venneri A., Shanks M.F., Staff R.T. et al. Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease. NeuroReport 2002; 13: 83-87.
Venneri A., McGeown W.J., Shanks M.F. Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer's disease. NeuroReport 2005; 16: 107-110.
Venneri A., Lane R. Effects of cholinesterase inhibition on brain white matter volume in Alzheimer's disease. NeuroReport 2009; 20: 285-288.
Weiser M., Rotmensch H.H., Korczyn A. et al. A pilot, randomized, open-label trial assessing safety and pharmacokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances. Int J Geriat Psychiat 2002; 17: 343-346.
Wesnes K.A., McKeith I., Edgar C. et al. Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology 2005; 65: 1654-1656.
Winblad B., Grossberg G., Frolich L. et al. IDEAL: A 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007; 69: Suppl 1: S14-S22.
Winblad B., Machado J.C. Use of rivastigmine transdermal patch in the treatment of Alzheimer's disease. Expert Opin Drug Deliv 2008; 5: 1-10.
Wright C.I., Geula C., Mesulam M.M. Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability. Ann Neurol 1993; 34: 373-384.